HM101のライセンス契約を締結しました。
HIMUKA AM PHARAMA ENTERS INTO A LICENSE AGREEMENT OF ADRENOMEDULLIN
～難病に対する新規医薬品の開発に向けて～
当社は、株式会社ファーマフーズ（本社︓京都府京都市⻄京区）と、⽣理活性ペプチド「アドレノメデュリン」（開発コードHM101）に関するライセンス契約を締結いたしましたので、お知らせします。
本ライセンス契約に基づき、当社は、株式会社ファーマフーズに対し、以下の範囲で新規医薬品の研究開発および製造販売に関する独占的な権利を付与します。
・対象化合物︓アドレノメデュリン（開発コードHM101）
・対象疾患︓⽪質下梗塞と⽩質脳症を伴う常染⾊体優性脳動脈症（CADASIL）
・対象地域︓⽇本、韓国および台湾
当社は、アドレノメデュリンに関連して、改良型アドレノメデュリン（開発コードHM201︓PEG化アドレノメデュリン）の創薬開発を進めておりますので、引き続き新薬創出に向けた活動を強化してまいります。
■アドレノメデュリン
アドレノメデュリン（adrenomedullin）は、1993 年に北村和雄⽒（当社科学顧問、宮崎⼤学特別教授）、寒川賢治⽒（国⽴循環器病研究センター名誉研究所⻑）らによって発⾒された⽣理活性ペプチドです。アドレノメデュリンは、⾎管新⽣作⽤、組織再⽣作⽤、抗炎症作⽤等の多彩な作⽤を備えています。
■⽪質下梗塞と⽩質脳症を伴う常染⾊体優性脳動脈症（CADASIL）
NOTCH3遺伝⼦の変異を原因とする遺伝性の脳⾎管疾患で、我が国では厚⽣労働省により「指定難病」と認定されています。我が国での有病率は、成⼈⼈⼝10万⼈あたり1.20〜3.58⼈と推定されています。
リンク：プレスリリース（PDF）
Himuka AM Pharma Corp. today announced that it has entered into a license agreement with Pharma Foods International Co., Ltd. regarding the bioactive peptide adrenomedullin (development code: HM101).
Under the terms of the agreement, Himuka has granted Pharma Foods International exclusive rights in Japan, South Korea, and Taiwan for the development, manufacturing, and commercialization of a novel therapeutic candidate utilizing an adrenomedullin formulation for the treatment of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and
Leukoencephalopathy (CADASIL).
Furthermore, Himuka is concurrently advancing the drug development of a long-acting adrenomedullin derivative (development code: HM201). The company will continue to devote resources to the development of HM201, and remains committed to advancing new treatment options for patients with unmet medical needs worldwide.
About Adrenomedullin
Adrenomedullin is a bioactive peptide discovered in 1993 by Dr. Kitamura, Dr. Kangawa, et al. Adrenomedullin possesses diverse actions, including angiogenesis, tissue regeneration, and anti-inflammatory effects. Himuka has coded the development of adrenomedullin as HM101.
About CADASIL
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and
Leukoencephalopathy (CADASIL) is a hereditary cerebrovascular disorder caused by mutations in the NOTCH3 gene. It is designated as an intractable disease by the Ministry of Health, Labor and Welfare in Japan. The prevalence in Japan is estimated to be 1.20 to 3.58 cases per 100,000 adults.
About Himuka
Himuka AM Pharma Cop. is a multi-asset, clinical-stage biopharmaceutical company focused on developing novel treatments for unmet needs, including refractory Inflammatory bowel disease.
Himuka has been selected for the J-Startup program by the Japan Ministry of Economy, Trade and Industry.
For more information, visit https://www.himuka-am.com/
Forward-Looking Statements
This press release may contain forward-looking statements.
Statements contained in this press release concerning plans, predictions, and strategies to improve future performance (“Forward-Looking Statements”) are based on information currently available to Himuka’s management, and inevitably involve a certain element of risk and uncertainties.
Actual results may therefore differ from those in the Forward-Looking Statements. Therefore, forward-looking statements should not be relied upon as representing Himuka’s views as of any date after the date of this press release.
ref:PressRelease（PDF）